Cambridge Laboratories, Helsinn Healthcare SA sales and marketing update

Cambridge launched Aloxi palonosetron in the U.K. to prevent nausea and vomiting induced by chemotherapy. Cambridge has U.K. marketing rights to the serotonin (5-HT3) receptor antagonist under a 200...